Drug profile · INN
ivabradine
APO-IVABRADINE
ivabradine (APO-IVABRADINE) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Associated with Servier Laboratories (Aust.) Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — ivabradine
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
ivabradine (APO-IVABRADINE) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Associated with Servier Laboratories (Aust.) Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
Primary target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ivabradine?
ivabradine (APO-IVABRADINE) is a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker. Associated with Servier Laboratories (Aust.) Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ivabradine?
APO-IVABRADINE is a marketed brand name for ivabradine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ivabradine?
ivabradine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.